Search

CancerNetwork®
CancerNetwork® @CancerNetwrk ·
The FDA has approved a label update for nadofaragene firadenovec to enhance efficient clinical preparation for health care teams, clearing the way for an accelerated 25-minute water-bath thawing method. ⬇️ Learn more ⬇️ hubs.li/Q048Hdf50 #blcsm #BladderCancer #NMIBC #Oncology
Nadofaragene Firadenovec Label Update Approved in BCG-Unresponsive NMIBC | CancerNetwork
Nadofaragene Firadenovec Label Update Approved in BCG-Unresponsive NMIBC | CancerNetwork

The FDA previously approved the gene therapy as a treatment for high-risk BCG-unresponsive NMIBC with CIS plus or minus papillary tumors in December 2022.

From cancernetwork.com
105
Mirrors of Medicine
Mirrors of Medicine @mirrorsmed ·
Blood and Urine Circulating Tumor DNA in Urothelial Bladder Cancer: State of the Art and Clinical Perspective sciencedirect.com/science/articl… Circulating tumor DNA (ctDNA) is an emerging non-invasive biomarker in urothelial #BladderCancer with diagnostic, prognostic, and predictive value. This systematic review found strong concordance between ctDNA and tumor mutations, supporting its role in real-time disease monitoring. ctDNA positivity predicted poorer survival outcomes, while clearance correlated with treatment response. Despite promising results, variability in methods and limited data highlight the need for standardization and ongoing phase III validation. @AmirHorowitz @laconss @FAudenet @OncoAlert 🚨
4
798
VJ Oncology
VJ Oncology @VJOncology ·
Armine Smith at #GU26 highlights why survivorship must be central in women with #BladderCancer 💙 Beyond oncologic outcomes, focus on QoL, organ preservation & early conversations on intimacy and counselling 🗣️🩺 Watch: ow.ly/I2Ef50YxJ6t #gusm #oncology #survivorship
Reducing sexual dysfunction in female patients with bladder cancer

Armine Smith, MD, Johns Hopkins University School of Medicine, Baltimore, MD, discusses the importance of considering survivorship and quality of life issues in women with bladder cancer, beyond...

From vjoncology.com
52
ActionBladderCancer
ActionBladderCancer @Actionbladderca ·
We are supporting an important research study led by Birkbeck College, University of London. Researchers are looking to better understand people’s experiences of being diagnosed & treated for cancer. Prof Anne Miles: ae.miles@bbk.ac.uk #bladdercancer
45
World Bladder Cancer Patient Coalition
World Bladder Cancer Patient Coalition @WorldBladderCan ·
#Bladdercancer is common in Europe, yet still under-recognised. Many miss early symptoms and face unequal access to information. @EU_BClear is working to change this 🇪🇺 🔹 Raise awareness 🔹 Support earlier detection 🔹 Improve access to information 🔹 Strengthen shared decision-making Learn more 👇 patients.uroweb.org/bclear-bladder… #BladderCancer #HealthLiteracy #EUHealth @WoncaEurope @Uroweb @EU_Commission @CancerLeagues @erasmusmcintl @EU_HaDEA @PTUweb
2
139
UroToday.com
UroToday.com @urotoday ·
Phase 3 #KEYNOTE905 trial investigates enfortumab vedotin plus pembrolizumab in cisplatin-ineligible #BladderCancer. Christof Vulsteke, MD, PhD @crighent joins @UroDocAsh @MDAndersonNews to discuss how perioperative enfortumab vedotin + pembrolizumab emerges as a powerful option for cisplatin-ineligible #MIBC. The regimen delivers impressive response and survival benefits while maintaining surgical safety, signaling a major step forward in the perioperative treatment landscape. #WatchNow > bit.ly/4tUkOv5
374
Vadim Koshkin MD
Vadim Koshkin MD @koshkin85 ·
Excited for this Webinar later today discussing ctDNA in #BladderCancer with my @UCSFCancer @UCSFHospitals colleague @snseyedinMD A dynamic and rapidly changing space with better biomarkers now available @PGrivasMDPhD @shilpaonc @IBCG_BladderCA @BladderCancerUS
Natera Natera @NateraGenetics ·
Reserve your spot today for our upcoming webinar, From ASCO GU to real-world practice: Personalized tumor-informed #ctDNA in bladder cancer management. @koshkin85, Genitourinary Medical Oncology and @snseyedinMD, Radiation Oncology will share how leading clinicians are using ctDNA to guide management decisions. Key discussion topics: -ASCO GU data updates in bladder cancer, including RETAIN1/2, INDIBLADE, NIAGARA, and IMvigor011 -Operationalizing bladder-sparing decisions using ctDNA treatment response monitoring after neoadjuvant therapy -Molecular relapse and ctDNA timing considerations in the post-cystectomy setting -Case-based discussion highlighting real-world decision points and multidisciplinary coordination. Register here: ow.ly/ZSXo50Ys36g
Upcoming Webinar

From ASCO GU to Real-World Practice: ctDNA in Bladder Cancer Management

From info.natera.com
1
746
Bradd Pavur, APR
Bradd Pavur, APR @BraddPavur ·
ICYMI: @MaryWDunn with @UNCurology provides many excellent insights and practical suggestions for #bladdercancer patients and their family members. @EverydayHealth @UNC_SOM Watch here: ow.ly/oSym50Ywz9A
Team Up With Your Provider for Better Metastatic Bladder Cancer Care
From everydayhealth.com
Urology@UNC Urology@UNC @UNCurology ·
You’re not just a patient, you’re part of the decision-making process. This conversation highlights how speaking up, asking questions, and sharing your goals can shape your care. Watch here:ow.ly/oSym50Ywz9A @MaryWDunn @EverydayHealth @UNCurology @UNC_SOM @UNC_Lineberger
1
171